ATE297941T1 - Verfahren zur herstellung von einer kristallinen form ii von clarythromycin - Google Patents

Verfahren zur herstellung von einer kristallinen form ii von clarythromycin

Info

Publication number: ATE297941T1
Authority: AT; Austria
Prior art keywords: clarithromycin; water; trimethylsilyl; oxime; group
Prior art date: 2000-03-15

Application number

AT01106198T

Other languages

English (en)

Inventor

Kwee-Hyun Suh

Sang-Min Yun

Mi-Ra Seong

Gi-Jeong Kim

Gwan-Sun Lee

Nam-Du Kim

Original Assignee

Hanmi Pharm Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-15

Filing date

2001-03-14

Publication date

2005-07-15

2000-03-15 Priority claimed from KR1020000013033A external-priority patent/KR100361397B1/ko

2000-11-23 Priority claimed from KR10-2000-0069834A external-priority patent/KR100367981B1/ko

2001-03-14 Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE297941T1 publication Critical patent/ATE297941T1/de

Links

238000004519 manufacturing process Methods 0.000 title 1
229960002626 clarithromycin Drugs 0.000 abstract 6
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000003960 organic solvent Substances 0.000 abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
KYTWXIARANQMCA-RWJQBGPGSA-N (3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2 Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=NO)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-RWJQBGPGSA-N 0.000 abstract 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 1
229930006677 Erythromycin A Natural products 0.000 abstract 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
229960003276 erythromycin Drugs 0.000 abstract 1
229940098779 methanesulfonic acid Drugs 0.000 abstract 1
239000012022 methylating agents‎ Substances 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
125000003544 oxime group Chemical group 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT01106198T 2000-03-15 2001-03-14 Verfahren zur herstellung von einer kristallinen form ii von clarythromycin ATE297941T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020000013033A KR100361397B1 (ko)	2000-03-15	2000-03-15	에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
KR10-2000-0069834A KR100367981B1 (ko)	2000-11-23	2000-11-23	클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물

Publications (1)

Publication Number	Publication Date
ATE297941T1 true ATE297941T1 (de)	2005-07-15

Family

ID=36274127

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01106198T ATE297941T1 (de)	2000-03-15	2001-03-14	Verfahren zur herstellung von einer kristallinen form ii von clarythromycin
AT04013295T ATE338053T1 (de)	2000-03-15	2001-03-14	Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT04013295T ATE338053T1 (de)	2000-03-15	2001-03-14	Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität

Country Status (15)

Country	Link
US (1)	US6515116B2 (de)
EP (2)	EP1134229B1 (de)
JP (1)	JP4119125B2 (de)
CN (1)	CN1193036C (de)
AT (2)	ATE297941T1 (de)
AU (1)	AU771825B2 (de)
BR (1)	BR0109194A (de)
CA (1)	CA2402201C (de)
DE (2)	DE60122791T2 (de)
ES (2)	ES2242668T3 (de)
HU (1)	HUP0300418A3 (de)
MX (1)	MXPA02008861A (de)
NZ (1)	NZ521184A (de)
RU (1)	RU2230748C2 (de)
WO (1)	WO2001068662A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en) *	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
EP1313486A1 (de) *	2000-02-29	2003-05-28	Teva Pharmaceutical Industries Ltd.	Verfahren zur herstellung des clarithromycins und eines clarithromycin-zwischenprodukt; clarithromycin wesentlich frei von oxime; und pharmazeutische zusammensetzung die sie enthalten
KR100367981B1 (ko) *	2000-11-23	2003-01-14	한미약품공업 주식회사	클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
NZ521368A (en) *	2000-03-28	2004-05-28	Biochemie Ges M	Granulated particles of an active compound, with a film-forming coating resulting in the masked taste of said active compound
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en) *	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US20020197314A1 (en) *	2001-02-23	2002-12-26	Rudnic Edward M.	Anti-fungal composition
US20060083759A1 (en) *	2002-07-17	2006-04-20	Aleksander Resman	Stabilization of the profile of release of active substances from a formulation
EP3738591A3 (de)	2003-03-10	2021-03-24	Merck Sharp & Dohme Corp.	Neuartige antibakterielle wirkstoffe
ES2221807B1 (es) *	2003-06-24	2005-12-16	Ercros Industrial, S.A.	Un procedimiento para la obtencion de claritromicina.
JP2006528190A (ja) *	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
EP1648415A4 (de) *	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
EP1648418A4 (de) *	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
AU2004264939A1 (en) *	2003-08-11	2005-02-24	Middlebrook Pharmaceuticals, Inc.	Robust pellet
AU2004264356B2 (en)	2003-08-12	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
JP5686494B2 (ja) *	2003-08-29	2015-03-18	シオノギインコーポレイテッド	抗生物質製剤、その使用法及び作成方法
WO2005027877A1 (en) *	2003-09-15	2005-03-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
CA2572292A1 (en) *	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
CN101073284B (zh) *	2005-02-07	2010-05-05	中兴通讯股份有限公司	一种控制系统间测量和频间测量的方法
WO2007015265A2 (en) *	2005-05-24	2007-02-08	Kopran Research Laboratories Ltd	A process for preparing 6,9-imino ether
WO2007008537A2 (en) *	2005-07-07	2007-01-18	Elan Pharma International, Limited	Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) *	2005-08-31	2007-04-05	Alembic Limited	Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) *	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (de)	2007-08-17	2009-03-04	Abbott GmbH & Co. KG	Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
US9453042B2 (en) *	2007-10-25	2016-09-27	Cempra Pharmaceuticals, Inc.	Process for the preparation of macrolide antibacterial agents
CN107854477A (zh)	2008-10-24	2018-03-30	森普拉制药公司	使用含三唑的大环内酯治疗抗性疾病的方法
CN101787063B (zh) *	2009-01-23	2012-12-19	刘力	抗感染药物及其制备和用途
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
CN108310000A (zh)	2009-09-10	2018-07-24	森普拉制药公司	治疗疟疾、结核病和mac疾病的方法
US8975386B2 (en)	2010-03-22	2015-03-10	Cempra Pharmaceuticals, Inc.	Crystalline forms of a macrolide, and uses therefor
CN102917708B (zh)	2010-05-20	2015-11-25	森普拉制药公司	制备大环内酯和酮内酯及其中间体的方法
KR20180110181A (ko)	2010-09-10	2018-10-08	셈프라 파마슈티컬스, 인크.	질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
SG11201405895UA (en)	2012-03-27	2014-10-30	Cempra Pharmaceuticals Inc	Parenteral formulations for administering macrolide antibiotics
CN103897002A (zh) *	2012-12-31	2014-07-02	菏泽市方明制药有限公司	一种粗品硫氰酸红霉素制备红霉素a9-肟的方法
CN103087130B (zh) *	2013-02-06	2015-12-23	浙江国邦药业有限公司	一种克拉霉素晶型转换方法
US9861616B2 (en)	2013-03-14	2018-01-09	Cempra Pharmaceuticals, Inc.	Methods for treating respiratory diseases and formulations therefor
MX356772B (es)	2013-03-15	2018-06-13	Cempra Pharmaceuticals Inc	Procesos convergentes para la preparacion de agentes antibacterianos macrolidos.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60214796A (ja) *	1984-04-06	1985-10-28	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシン類の製法
US4670549A (en) *	1985-03-18	1987-06-02	Taisho Pharmaceutical Co., Ltd.	Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) *	1986-09-18	1993-04-08	Taisho Pharma Co Ltd	Erythromycin-a-derivate und verfahren zu ihrer herstellung.
KR960000434B1 (ko) *	1986-12-17	1996-01-06	다이쇼 세이야꾸 가부시끼가이샤	에리스로마이신 a유도체 및 그의 제조 방법
SI9011409A (en) *	1990-07-18	1995-10-31	Pliva Pharm & Chem Works	O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
US5872229A (en) *	1995-11-21	1999-02-16	Abbott Laboratories	Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) *	1996-04-02	1998-11-17	Abbott Laboratories	9-oximesilyl erythromycin a derivatives
WO1998004574A1 (en) *	1996-07-29	1998-02-05	Abbott Laboratories	Preparation of crystal form ii of clarithromycin
US5858986A (en) *	1996-07-29	1999-01-12	Abbott Laboratories	Crystal form I of clarithromycin
US5945405A (en) *	1997-01-17	1999-08-31	Abbott Laboratories	Crystal form O of clarithromycin
US5864023A (en) *	1997-02-13	1999-01-26	Abbott Laboratories	3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
IL135792A0 (en) *	1997-12-01	2001-05-20	Abbott Lab	6-o-alkyl derivatives of erythronolide b
US6258785B1 (en) *	1998-12-02	2001-07-10	Pfizer Inc.	Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin

2001
- 2001-03-14 ES ES01106198T patent/ES2242668T3/es not_active Expired - Lifetime
- 2001-03-14 AT AT01106198T patent/ATE297941T1/de not_active IP Right Cessation
- 2001-03-14 EP EP01106198A patent/EP1134229B1/de not_active Expired - Lifetime
- 2001-03-14 AU AU42827/01A patent/AU771825B2/en not_active Ceased
- 2001-03-14 EP EP04013295A patent/EP1469008B1/de not_active Expired - Lifetime
- 2001-03-14 JP JP2001567752A patent/JP4119125B2/ja not_active Expired - Fee Related
- 2001-03-14 DE DE60122791T patent/DE60122791T2/de not_active Expired - Lifetime
- 2001-03-14 WO PCT/KR2001/000394 patent/WO2001068662A1/en not_active Ceased
- 2001-03-14 BR BR0109194-8A patent/BR0109194A/pt not_active IP Right Cessation
- 2001-03-14 NZ NZ521184A patent/NZ521184A/en unknown
- 2001-03-14 DE DE60111438T patent/DE60111438T2/de not_active Expired - Lifetime
- 2001-03-14 RU RU2002127591/04A patent/RU2230748C2/ru not_active IP Right Cessation
- 2001-03-14 MX MXPA02008861A patent/MXPA02008861A/es active IP Right Grant
- 2001-03-14 US US09/805,831 patent/US6515116B2/en not_active Expired - Fee Related
- 2001-03-14 ES ES04013295T patent/ES2270226T3/es not_active Expired - Lifetime
- 2001-03-14 CA CA002402201A patent/CA2402201C/en not_active Expired - Fee Related
- 2001-03-14 HU HU0300418A patent/HUP0300418A3/hu unknown
- 2001-03-14 AT AT04013295T patent/ATE338053T1/de not_active IP Right Cessation
- 2001-03-14 CN CNB018096050A patent/CN1193036C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1193036C (zh)	2005-03-16
HUP0300418A2 (hu)	2003-06-28
NZ521184A (en)	2004-02-27
WO2001068662A1 (en)	2001-09-20
ES2242668T3 (es)	2005-11-16
MXPA02008861A (es)	2003-02-10
RU2002127591A (ru)	2004-02-27
ATE338053T1 (de)	2006-09-15
ES2270226T3 (es)	2007-04-01
CN1429233A (zh)	2003-07-09
RU2230748C2 (ru)	2004-06-20
EP1469008A1 (de)	2004-10-20
DE60111438T2 (de)	2006-05-18
JP2004500398A (ja)	2004-01-08
CA2402201C (en)	2007-06-05
JP4119125B2 (ja)	2008-07-16
EP1134229B1 (de)	2005-06-15
EP1134229A2 (de)	2001-09-19
EP1469008B1 (de)	2006-08-30
BR0109194A (pt)	2003-02-11
AU4282701A (en)	2001-09-24
DE60122791T2 (de)	2007-10-04
DE60122791D1 (de)	2006-10-12
HUP0300418A3 (en)	2003-09-29
DE60111438D1 (de)	2005-07-21
EP1134229A3 (de)	2002-02-27
AU771825B2 (en)	2004-04-01
US20010039333A1 (en)	2001-11-08
CA2402201A1 (en)	2001-09-20
US6515116B2 (en)	2003-02-04

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE297941T1 (de)	2005-07-15	Verfahren zur herstellung von einer kristallinen form ii von clarythromycin
ATE232211T1 (de)	2003-02-15	Verfahren zur herstellung von form ii kristallen des clarithromycins
EP1070077B1 (de)	2003-05-28	15-gliedrige ketolid-lactame mit antibakterieller wirkung
DE69825785D1 (de)	2004-09-23	Verfahren zur herstellung von 6-o-methylerythromycin a unter verwendung von 9-hydroxyerythromycinderativen
DE69836697T2 (de)	2007-10-04	Neue 3,6-Hemiketale der 9a-Azalidklasse
DE60031154D1 (de)	2006-11-16	Verfahren zur herstellung von clarithromycin
ATE309262T1 (de)	2005-11-15	Verfahren zur herstellung von aufgereinigtem anthocyanin und kristallines anthocyanin
DE60029439T2 (de)	2007-02-01	Neue 8a- und 9a-lactame mit 15 ringatomen
WO2002018403A1 (fr)	2002-03-07	Procede permettant la production d'un derive d'erythromycine
DE69613971T2 (de)	2002-04-04	Oligonukelotide mit transversalkovalenter bindung, verfahren zu ihrer herstellung und darin benutztes synthon
EP0262905A2 (de)	1988-04-06	Modifizierungen in 3-0-Demethyl-Mycinose in Macrocin und Lactenocin
ES2195727A1 (es)	2003-12-01	Un procedimiento para la obtencion de claritromicina.
HUP0201693A2 (en)	2002-10-28	Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative, process for producing it and its pharmaceutical composition
DE69704778D1 (de)	2001-06-13	Verfahren zur herstellung von salzen von erythromicyn, roxithromicyn, clarythromicyn und azithromycin
ATE238331T1 (de)	2003-05-15	Neue hydroxyderivate von tylosin und verfahren zu deren herstellung
ES2221807B1 (es)	2005-12-16	Un procedimiento para la obtencion de claritromicina.
WO1998041532A1 (en)	1998-09-24	Erythromycin a oxime dihydrate
KR890000510A (ko)	1989-03-15	3'- 아지도-3'- 데옥시미딘의 신규화학적 제조방법
DD271332A1 (de)	1989-08-30	Verfahren zur herstellung von ribonucleotiden
DE60205912D1 (de)	2005-10-06	Verfahren zur herstellung einer erythromycinverbindung
MXPA00009875A (es)	2001-11-21	Cetolidos de lactamas de 15 miembros con actividad antibacteriana
EP0972778A1 (de)	2000-01-19	Erythromycin A Derivate und Verfahren zu deren Herstellung
WO2003040162A1 (de)	2003-05-15	Verfahren zur herstellung von desclarithromycin, sowie zwischenprodukte
DK153883B (da)	1988-09-19	Analogifremgangsmaade til fremstilling af antibiotiske salte af trimethylammoniumderivater af polyenmacrolider indeholdende en alifatisk aminogruppe